Introduction {#s1}
============

MicroRNAs are short non-coding RNAs. It plays a vital role in the regulation of many important biological processes ([@B2]; [@B12]; [@B37]). It has shown that human disease is associated with abnormal expression of miRNAs, whose analyses can guide the diagnosis, prognosis and treatment of certain diseases ([@B17]). However, identifying new miRNA--disease associations through bio-wet experiments not only has a high error rate, but also consumes huge financial resources ([@B9]). Therefore, *in-silicon* prediction of disease-associated miRNAs has become a critical step in prioritizing most confident targets for further experimental validation. Due to the growing power of sequencing technology, more and more omics data have been published ([@B35]), which provides a chance to reveal what role miRNAs play in physiology and pathology. Typical directions include miRNAs--disease interaction prediction, miRNA--miRNA regulatory module discovery, and so on ([@B7]). Undoubtedly, all these studies enrich our understanding of the functional regulation mechanisms of miRNA ([@B11]).

In recent years, in order to understand the pathogenesis of diseases, more and more computational models have been proposed by researchers to infer disease-related miRNAs, among which machine learning-based and network-based methods are most popular ([@B20]). Network-based methods are based on a common assumption that miRNAs associated with diseases using similar phenotypes are similar in function, and vice versa. For example, [@B14] proposed the priority of disease-associated miRNAs through human peptide--microRNAome networks to identify potential associations. However, this method relies too much on known associations to make its prediction performance less effective. Subsequently, [@B5] implemented a random walk with restart (RWRMDA) on its network to identify potentially associated miRNAs by building a network of similarities between miRNAs. Similarly, [@B26] conducted random walks through functional linkages between miRNA targets and disease genes to explore the relationship between human miRNA diseases. [@B23] constructed a multiple biological network by integrating the two-way relationship among microRNA, disease and environmental factors, and realized the unbalanced random walk algorithm on this network to achieve the purpose of prediction. However, these methods cannot predict miRNAs associated with isolated diseases. Later, [@B4] used a network of consistent reasoning methods to infer unknown miRNAs associated with disease. [@B10] created a network consistent projection algorithm to identify latent associations by integrating similarity networks and associated networks. The biggest advantage of these methods is that they can predict isolated disease-associated miRNAs, but the performance achieved is not very satisfactory.

More recently, machine learning-based models have been implemented to improve classification accuracy and prediction performance ([@B10]). For example, [@B32] designed a support vector machine (SVM) classifier that combines four topological features extracted from a miRNA target disease network to distinguish between prostate cancer-associated miRNAs and non-prostate cancer-associated miRNAs. To construct a negative sample, they randomly paired the miRNA with the disease and then removed the pair present in the positive sample set. It is clear that negative samples constructed in this way are prone to false positives. [@B3] introduced a normalized least square method to identify the association between potential miRNAs--diseases (RLSMDA), which does not require negative samples. In addition, [@B21] developed a Kronecker regularized least squares method to predict the potential association of miRNAs--disease by combining multiple omics data. [@B18] converted the miRNAs--disease association prediction problem into a complete bipartite graph model, and proposed a prediction algorithm based on a restricted Boltzmann machine to improve prediction performance. [@B25] introduced the cooperative matrix decomposition (CMFMDA) algorithm in the recommendation system to infer potential associations. Finally, [@B6] introduced an induction matrix-completed algorithm to identify unknown associations. However, these methods do not perform well in predicting associations related to new diseases or miRNAs, and the prediction accuracy is not as satisfactory as associations with known diseases or miRNAs.

In order to achieve better predictive performance, we construct a new model called probability matrix factorization (PMFMDA) to predict unknown miRNAs--disease associations in this study. PMFMDA makes full use of miRNA disease association, miRNA similarity and disease similarity. To evaluate the effectiveness of PMFMDA, we test it using frameworks of global 5-fold CV and global LOOCV. In addition, a validation method called *CV* *~d~* is developed to estimate the performance in predicting novel diseases or miRNAs. Outperforming other state-of-the-arts methods, PMFMDA achieve reliable performance in the frameworks of global LOOCV and 5-fold CV (AUCs of 0.9237 and 0.9187, respectively) in the HMDD (V2.0) dataset ([@B16]). To further demonstrate the superiority of PMFMDA, we conduct an analysis of three common diseases. According to the analysis of the test results, we can find that there are 20, 19 and 17 of 20 candidate miRNAs that are confirmed to be associated with esophageal neoplasms, breast neoplasms and lung neoplasms by dbDEMC and miRCancer, respectively.

Materials and Methods {#s2}
=====================

The general workflow of PMFMDA is shown in [**Figure 1**](#f1){ref-type="fig"}. We first use matrix Y to represent 5,430 experimentally validated associations after preprocessing the HMDD V2.0 database ([@B16]). Specifically, Y is a 495 × 383 matrix with row denoting miRNAs and column denoting diseases; Y*~i,j~* = 1 if the *i* *^th^* miRNA is associated with the *j* *^th^* disease and 0 otherwise. We then calculate the disease similarity *S* *~d~* and miRNA similarity *S* *~m~*. Finally, a probability matrix factorization (PMF) model is proposed by integrating Y, *S* *~d~* and *S* *~m~*, the solution of which will recover unknown miRNAs--disease associations based on known ones.

![The workflow of PMFMDA is used to infer disease-associated unknown miRNAs.](fgene-10-01234-g001){#f1}

Disease Semantic Similarity {#s2_1}
---------------------------

The hierarchical directed acyclic graphs (DAGs), usually are obtained from the MeSH database, and are widely used to calculate the similarity between diseases ([@B10]). Specifically, for a disease *d*, let *DAGd* = (*d*, *T* *~d~*, *E* *~d~*) represents its directed acyclic graph, where *T* *~d~* denotes the set of the ancestors of *d*, and *E* *~d~* represents the set of links in the MeSH tree. So, the semantic contribution of disease *t* to disease *d* is defined as:

D

d

(

t

)

=

{

1

i

f

t

=

d

m

a

x

{

∆

×

D

d

(

t

′

)

\|

t

′

∈

c

h

i

l

d

r

e

n

o

f

t

}

i

f

t

≠

d

Where Δ is a predefined sematic contribution factor, the value of Δ in this study is set to 0.5. Therefore, we can calculate the semantic similarity of between diseases by formula (2).
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miRNAs Functional Similarity {#s2_2}
----------------------------

For the similarity between miRNAs, most studies use functional similarity measurements ([@B29]). Specifically, for any two miRNAs *r* *~i~* and *r* *~j~*, let *DT* *~i~* = {*d* *~i~* ~1~,*d* *~i~* ~2~,...,*d* *~i~* ~k~} and *DT* *~j~* = {*d* *~j~* ~1~,*d* *~j~* ~2~,...,*d* *~jl~*} be their associated disease sets, respectively. Similar to Wang et al. we first use $S(d,~DT) = \overset{max}{d_{i} \in DT}D(d,d_{i})$ to represent the similarity between a disease *d* and *DT*. Then the similarity between *r* *~i~* and *r* *~j~* is defined as
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The Gaussian Interaction Profile Kernel Similarity For Diseases and miRNAs {#s2_3}
--------------------------------------------------------------------------

In the similarity measurement algorithm, Gaussian interaction profile kernel similarity is also a good measurement algorithm, which is widely used in various fields ([@B19]). Let *VP*(*d* *~i~*) be the vector associated with the disease *d* *~i~* in Y, i.e. the *i* *^th^* column of Y. Then, the Gaussian interaction kernel similarity between disease *d* *~i~* and *d* *~j~* is calculated as:
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where γ*~d~* is the adjustment parameter of the kernel bandwidth. The parameter γ*~d~* update rule is as follows:
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where $\gamma_{d}^{'}$ is usually set to 1.

Similarly, we can conclude that the Gaussian kernel similarity of miRNAs is as follows:
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Where $\gamma_{m}^{'}$ is usually set to 1.

Integrated Similarity For Diseases and miRNAs {#s2_4}
---------------------------------------------

The similarity between disease *d* *~i~* and disease *d* *~j~* is constructed by combining the two similarities of the disease as follows:
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Similarly, the similarity between miRNAs *r* *~i~* and *r* *~j~* can be redefined as:
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PMFMDA {#s3}
======

Probability Matrix Decomposition (PMF) is a probabilistic linear model of Gaussian observation noise and has been widely used in data representation ([@B24]). Let *Y*∈*R* *^n×m^* be the known miRNAs--disease association matrix, *U* *~i~* and *V* *~i~* represent the D-dimensional miRNA-specific and disease-specific latent feature vectors, respectively. The conditional distribution of the observed associations *Y*∈*R* *^n×m^* (likelihood term) and the prior distribution of *U*∈*R* *^D×n^* and *V*∈*R* *^D×m^* are given by:
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Where *N* (*x* \| *µ*,α^-1^) denotes the Gaussian distribution, *I* *~ij~* = 0 if the entry(*i,j*) in *Y* is missing, and 1 otherwise.

The optimal model is obtained by maximizing the logarithmic a posterior of miRNAs and disease characteristics using fixed hyperparameters:
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Where C is a constant. So, using a quadratic regularization term to minimize the sum of squares of the error functions instead of maximizing the posterior distribution relative to U and V:
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Where *λ* *~U~* = *α* *~U~* / *α* and *λ* *~v~* = *α* *~V~* / *α* are regularization parameters, $\left| \middle| \cdot \middle| |_{Fro}^{2} \right.$ denotes the Frobenius norm.

The standard PMF in Equation (10) does not consider the effect of similarity between miRNAs and the similarity between diseases. Since *U* *~i~* represents the D-dimensional miRNA-specific latent feature vectors, *U* *^T^* *U* denotes the weighted similarity matrix of the miRNAs. Similarly, *V* *^T^* *V* denotes the weighted similarity matrix of the disease. Thus, we propose a new objective function by integrating miRNAs similarity and diseases similarity named PMFMDA as follows:
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where *S* *~m~* and *S* *~d~* have been calculated before.

Optimization {#s3_1}
------------

In order to obtain the local optimal solution of Equation (15), we use the gradient descent algorithm to solve ([@B30]). According to the nature of the Frobenius norm, the corresponding Lagrange function *L* *~E~* of Equation (15) is defined as:
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where *T* *~r~*() denotes the trace of a matrix, ∅=\[ϕ*~ik~*\] and Ψ=\[ω*~jk~*\] are Lagrangian multipliers.

The partial derivatives of *U* and *V* are as follows:
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Finally, the Karush-Kuhn-Tucker (KKT) conditions $\varphi_{ikU_{ik} = 0}$ and $\omega_{jkV_{Jk} = 0}$ according to the gradient descent method. The following equations are obtained for *U* *~ik~* and *V* *~jk~*:
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Therefore, the updating rules for *U* and *V* as follows:
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Update *U* and *V* according to Equation (19) and Equation (20) until the local minimum of the objective function. Finally, the predicted miRNAs--disease association matrix is *Y* *^′^*=*U* *^T^* *V*. The *i*th column of *Y*′ indicates the association score between disease *d* *~i~* and miRNAs, and the larger the score, the more relevant it is.

Evaluation Methods {#s3_2}
------------------

In order to test the performance of PMFMDA, we utilize a 5-fold CV experiment and global LOOCV on the HMDD database and compare it with a few recent methods including CMFMDA, IMCMDA, NCPMDA, RLSMDA, and RWRMDA. In the 5-fold CV experiment of a single disease *d*, known miRNAs associated with *d* (column vectors in matrix A∈R^m×n^) are randomly divided into five subsets of equal size. Associations related to all other diseases together with 4 subsets (with respect to *d*) are taken as training samples and the remaining subset is considered as testing samples. The process is performed for 5 times until all the associations associated with d have been predicted once. Global LOOCV was used to evaluate the model's global prediction ability for all miRNAs--disease association simultaneously. Specifically, we removed each known association in turn as a testing sample, with all remaining associations as training samples. We then predicted the removed entry and evaluated the performance. In addition, we perform *CV* *~d~* experiment to test the performance of PMFMDA in predicting miRNAs associated to a novel disease *d.* In *CV* *~d~*: CV on disease *d* *~i~*, we remove all the known associations of the disease *d* *~i~* (column vectors in matrix *Y*∈R^m×n^) and build prediction model (for inferring the deleted associations) using the remaining data.

Parameter Tuning {#s3_3}
----------------

We cross-validate the training set to tune the parameters of PMFMDA. Specifically, the parameters *λ* *~U~*,*λ* *~V~*,*λ* ~1~, and *λ* ~2~ are increased from 0.001 to 1 with a step of 0.1 and the ones with the best AUC are selected. Since the other methods have also been tested on HMDD (V2.0) in published papers, we adopt the parameters provided by the authors. Specifically, *W*=0.9 for RLSMDA, *λ* *~U~* = *λ* *~V~* = 1,*λ* ~1~ = *λ* ~2~ = 0.005 for PMFMDA, *λ* ~1~ = *λ* ~2~ = 1 for IMCMDA, *λ* *~m~* = *λ* *~d~* = 1 for CMFMDA *r* = 0.9, for RWRMDA and NCPMDA is parameter free.

Results {#s4}
=======

PMFMDA Outperforms Other Popular Methods In Predicting Potential Associations {#s4_1}
-----------------------------------------------------------------------------

We apply PMFMDA, CMFMDA, IMCMDA, NCPMDA, RLSMDA, and RWRMDA into the HMDD database. Their receiver operating characteristic (ROC) curves and associated area under the curve (AUCs) of the global 5-fold CV and LOOCV are plotted in [**Figure 2**](#f2){ref-type="fig"}. As can be seen, the AUCs of PMFMDA, CMFMDA, IMCMDA, NCPMDA, RLSMDA, and RWRMDA are 0.9187, 0.8928, 0.8372, 0.8792, 0.8333, and 0.8168, respectively. Furthermore, PMFMDA also achieve the best AUC (0.9237) on global LOOCV, indicating that PMFMDA perform best in predicting miRNAs--disease associations. However, considering the limited number of known miRNAs--disease associations, it might be insufficient to evaluate the performance of the methods by AUC alone. Thus, we also plotted the precise recall (PR) curve and calculated the area under the PR curve (AUPR) based on the global 5-fold CV experiment in [**Figure 3**](#f3){ref-type="fig"}. In a PR-curve, the precision refers to the ratio of correctly predicted associations to all associations with scores higher than a given threshold; by contrast, the recall refers to the ratio of correctly predicted associations to all known miRNAs--disease associations. In general, the ROC curve and the PR curve show similar trend. As shown in [**Figure 3**](#f3){ref-type="fig"}, the AUPRs of PMFMDA, CMFMDA, IMCMDA, NCPMDA, RLSMDA, and RWRMDA are 0.3535, 0.3428, 0.2509, 0.1176, 0.1234, and 0.1369 respectively, indicating that PMFMDA performed best in predicting miRNAs--disease associations. At the same time, in order to further prove the effectiveness of PMFMDA. We performed 10 times of global 5-fold CV and achieved an average AUC and AUPR of 0.9187 +/− 0.0013, 0.3535+/− 0.0015, respectively. This proves the reliability and stability of the PMFMDA algorithm.

![The ROC curves for PMFMDA and benchmark algorithms for 5-fold CV and global LOOCV.](fgene-10-01234-g002){#f2}

![The PR curves for PMFMDA and benchmark algorithms for 5-fold CV.](fgene-10-01234-g003){#f3}

PMFMDA Outperforms Other Popular Methods In Predicting miRNAs Associated With Novel Diseases {#s4_2}
--------------------------------------------------------------------------------------------

Besides global miRNAs--disease predictions, it is also critical to check the performance of the above methods on specific diseases. *CV* *~d~* is used to measure the ability of an algorithm to predict a new disease-associated miRNA. In order to compare the fairness of the test, we conduct CV tests on 8 common diseases ([@B33]) and use the area under the accurate recall curve (AUPR) as an indicator of predictive performance. The reason is that AUPR severely penalizes highly ranked non-interactions, which is desirable here because in practice we do not want to recommend incorrect predictions (i.e., AUPR metrics severely penalize highly ranked false positives). The results for *CV* *~d~* are shown in [**Table 1**](#T1){ref-type="table"}. We can clearly see that the average AUPR of PMFMDA for the eight test diseases was 0.6687, which was significantly higher than IMCMDA (0.6377), CMFMDA (0.5091), NCPMDA (0.6121), and RLSMDA (0.5761). This also sufficient PMFMDA is also the best way to predict miRNAs associated with novel diseases.

###### 

Comparison of AUPR values predicted by PMFMDA and benchmark algorithms on novel diseases.

  Disease name       AURP                                
  ------------------ -------- -------- -------- -------- --------
  Melanoma           0.7149   0.6757   0.4574   0.6785   0.6940
  Breast tumor       0.7895   0.7752   0.6135   0.7866   0.7749
  Colorectal tumor   0.6585   0.6333   0.4725   0.5714   0.5315
  Glioblastoma       0.5940   0.5076   0.4540   0.4779   0.4028
  Heart failure      0.5956   0.6284   0.4510   0.6182   0.5510
  Prostatic tumor    0.6578   0.5881   0.5963   0.5873   0.5208
  Stomach tumor      0.6981   0.6438   0.5231   0.6269   0.6081
  Bladder tumor      0.6409   0.5388   0.5051   0.5505   0.5255
  Mean               0.6687   0.6237   0.5091   0.6121   0.5761

Furthermore, in order to further evaluate our approach in predicting new diseases. We implement *CV* *~d~* experiments on the above 8 diseases. We show the calculation of the number of disease-associated miRNAs identified at different ranking thresholds in [**Table 2**](#T2){ref-type="table"}. For example: We delete all miRNAs associated with breast tumors, and then use PMFMDA to predict its related miRNAs. we can find that 91 of the top 100 predictions are accurately predicted through the test results. This is ample indication that our approach can yield high quality predictions for isolated disease-associated miRNAs. In order to better understand the predicted eight disease-related miRNAs, we listed the names and predicted scores of the top 100 candidates related to the eight diseases in the [**Supplementary Table S1**](#SM1){ref-type="supplementary-material"}.

###### 

PMFMDA predicts the correct numbers of different ranking thresholds for 8 common diseases.

  Cancer                      No. of known associated miRNAs   Ranking threshold                  
  --------------------------- -------------------------------- ------------------- ---- ---- ---- ----
  Breast neoplasms            202                              20                  38   54   74   91
  Colorectal neoplasms        147                              17                  30   45   58   70
  Glioblastoma                96                               17                  30   36   43   53
  Heart failure               120                              17                  28   39   51   58
  Melanoma                    141                              19                  35   51   63   77
  Prostatic neoplasms         118                              17                  32   43   56   65
  Stomach neoplasms           173                              15                  32   49   63   79
  Urinary bladder neoplasms   92                               18                  31   42   51   55

Evaluate Performance on Different Data Sources {#s4_3}
----------------------------------------------

To further test the versatility of PMFMDA. We obtain 60,576 experimental validation correlation data by preprocessing the MNDR (V2.0) dataset ([@B8]). The data contains 887 diseases and 3,954 miRNAs. We apply PMFMDA, CMFMDA, IMCMDA, NCPMDA, RLSMDA, and RWRMDA on the MNDR (V2.0) database. As shown in [**Table 3**](#T3){ref-type="table"}, the AUC of PMFMDA was 0.9885, significantly higher than those of CMFMDA (0.9799), IMCMDA (0.9171), NCPMDA (0.9480), RLSMDA (0.9358), and RWRMDA (0.9055) with increases of about 0.86, 7.14, 4.05, 5.27, and 8.3% respectively. The AUPR of PMFMDA was 0.5174, significantly higher than those of CMFMDA (0.5047), IMCMDA (0.3865), NCPMDA (0.2045), RLSMDA (0.2818), and RWRMDA (0.1907). In conclusion, PMFDA has been proven to be effective in inferring related miRNAs with diseases in terms of AUC values and AUPR values.

###### 

The performance of PMFMDA and the baseline methods based on 5-fold CV on the MNDRV2.0 dataset.

         PMFMDA   CMFMDA   IMCMDA   NCPMDA   RLSMDA   RWRMDA
  ------ -------- -------- -------- -------- -------- --------
  AUC    0.9885   0.9799   0.9171   0.9480   0.9358   0.9055
  AUPR   0.5174   0.5047   0.3865   0.2045   0.2818   0.1907

Parameter Sensitivity Analysis {#s4_4}
------------------------------

In machine learning, parameter tuning is critical for the performance of a model. Thus, we presented in [**Table 4**](#T4){ref-type="table"} several sets of parameter settings based on the global 5-fold CV experiment on the HMDDV 2.0 dataset. We found that a better prediction result will be achieved when the value of *λ* ~1~ and *λ* ~2~ are large and the value of *λ* ~1~ and *λ* ~2~ are small. This result further confirms the effectiveness of seeking an optimal combination of parameters in improving performance.

###### 

Parameter tuning for PMFMDA based on 5-fold CV.

  AUC                        *λ* ~U~ = *λ* ~V~ = 1   *λ* ~U~ = *λ* ~V~ = 0.1   *λ* ~U~ = *λ* ~V~ = 0.01
  -------------------------- ----------------------- ------------------------- --------------------------
  *λ* ~1~ = *λ* ~2~ = 1      0.7905                  0.7728                    0.7588
  *λ* ~1~ = *λ* ~2~ = 0.1    0.9040                  0.8507                    0.8381
  *λ* ~1~ = *λ* ~2~ = 0.01   0.9185                  0.9032                    0.8692

Finally, we explore the effect of the disease similarity and miRNA similarity on prediction performance. Specifically, we perform global 5-fold CV with parameters *λ* ~1~ and *λ* ~2~ setting to zero ([**Figure 4**](#f4){ref-type="fig"}) in the HMDD (V2.0) dataset. We can see that the two similarities do contribute to prediction performance. In addition, PMFMDA achieve good results even in the model without integrating disease and miRNA similarity. However, this model is not good in predicting the association of new diseases or new miRNAs.

![Performance evaluation of PMFMDA in two situations for 5-fold cross validation. (1) PMFMDA with similarity information; (2) PMFMDA without similarity information.](fgene-10-01234-g004){#f4}

Case Studies {#s4_5}
------------

Another aspect of PMFMDA's strong predictive power is in case studies. Here, all the associations included in the HMDD (V2.0) database are used as training for the model, and the unincorporated associations are considered candidates for verification. In addition, miRCancer ([@B31]) and dbDEMC ([@B34]) were used to verify the correctness of the predictions. In this work, we mainly study three diseases including esophageal tumors, breast tumors, and lung tumors, and perform detailed analyses of the top 10 candidates predicted by PMFMDA in each disease (see [**Table 5**](#T5){ref-type="table"}).

###### 

PMFMDA infers the top 10 miRNA candidates for the three selected diseases.

  Cancer                 Number of miRNAs identified by the literature   Top 10                                                      
  ---------------------- ----------------------------------------------- -------- -------------- ------------------- ---- ---------- -------------------
  Esophageal neoplasms                                                   1        mir-17         dbDEMC              6    mir-1      dbDEMC
                                                                         2        mir-18a        dbDEMC              7    mir-200b   dbDEMC
                         10                                              3        mir-221        dbDEMC              8    mir-222    dbDEMC
                                                                         4        mir-16         dbDEMC              9    mir-29a    dbDEMC
                                                                         5        mir-19b        dbDEMC              10   mir-133b   dbDEMC
  Breast neoplasms                                                       1        mir-142        miRCancer           6    mir-138    dbDEMC
                                                                         2        mir-150        dbDEMC, miRCancer   7    mir-15b    dbDEMC
                         9                                               3        mir-106a       dbDEMC              8    mir-192    dbDEMC
                                                                         4        mir-99a        dbDEMC, miRCancer   9    mir-378a   Unconfirmed
                                                                         5        mir-130a       dbDEMC              10   mir-196b   dbDEMC
  lung neoplasms                                                         1        mir-16         dbDEMC              6    mir-99a    dbDEMC
                                                                         2        hsa-mir-15a    dbDEMC              7    mir-429    dbDEMC, miRCancer
                         9                                               3        hsa-mir-106b   dbDEMC              8    mir-302b   dbDEMC, miRCancer
                                                                         4        mir-195        dbDEMC, miRCancer   9    mir-130a   dbDEMC
                                                                         5        mir-141        dbDEMC              10   mir-296    Unconfirmed

Esophageal tumors are a disease with high morbidity and high mortality in the digestive system ([@B15]; [@B13]). Early diagnosis plays a crucial role in its treatment ([@B1]). In this study, we use PMFMDA to identify potential miRNAs associated with esophageal tumors. The top 10 miRNAs to be all confirmed by the database were associated with esophageal tumors (see [**Table 5**](#T5){ref-type="table"}).

Breast neoplasm is the malignant tumor that is prone to occur in women, it is a systemic malignant disease, for which many related genes have been discovered ([@B28]). MicroRNA (miRNA), as a kind of small RNA, can specifically bind to the 3′ untranslated region of its target mRNA, causing translational inhibition or degradation of target mRNA, and playing an oncogene in the process of cell growth and differentiation ([@B22]). Thus, MiRNAs present a new way for the study of pathogenic genes in breast neoplasms. As we can see from [**Table 5**](#T5){ref-type="table"}, 9 of the top 10 predictions have been confirmed by the relevant databases.

The death rate from lung neoplasms is extremely high. About 1.3 million people die of lung neoplasms every year, accounting for about one-third of all neoplasms deaths worldwide ([@B36]; [@B27]). miRNAs have been found as a tumor suppressor gene and lung neoplasms. For example, Gu et al. found that miR-99a was significantly expressed in lung cancer tissues and lung neoplasm cells. In addition, the expression level of miR-99a is correlated with clinicopathological factors, the clinical stage and lymph node metastasis of lung cancer patients. We use PMFMDA to predict potential related miRNAs in lung tumors. As shown in [**Table 5**](#T5){ref-type="table"}, we can find that only one of the top 10 related miRNAs predicted is unconfirmed.

For a clear view, we show the top 20 miRNAs associated networks predicting three tumors in [**Figure 5**](#f5){ref-type="fig"}. It is worth noting that some miRNA candidates are usually associated with several diseases. For example, mir-15b and mir-130a are associated with both Prostatic lung and Breast Neoplasms. Has-mir-16 is associated with both Esophageal Neoplasms and lung Neoplasms.

![The network of the top 20 predicted associations for the three selected diseases via PMFMDA.](fgene-10-01234-g005){#f5}

Discussion {#s5}
==========

It is known that miRNAs often play an irreplaceable role in biological processes related to human diseases ([@B25]). Accurately inferring disease-related potential miRNAs is helpful for us to investigate the pathogenesis of the disease and find a more effective treatment. In this study, we construct a mathematical model based on probability matrix factorization (PMFMDA) to identifying potential miRNAs--disease associations. PMFMDA outperform a few state-of-the-art models in the HMDD V2.0 database due to a few factors. First, PMFMDA not only uses known correlation data, but also integrates the similarities between miRNAs and between diseases. This has enabled PMFMDA to achieve good results in predicting isolated disease-associated miRNAs since theoretically similar miRNAs may associate with similar diseases. Second, the model is a semi-supervised model, which does not rely on negative samples. Thus, it is better than most machine learning algorithms with strong requirement for good negative samples. Finally, in the model solving process, we use the alternating gradient descent algorithm to find the optimal solution to ensure the reliability of disease feature vectors and miRNA feature vectors. In terms of experiment, PMFMDA achieves the highest AUC (0.9187, 0.9237, respectively) in 5-fold CV and global LOOCV, demonstrates its most reliable prediction performances. At the same time, we also perform *CV* *~d~* experiments to measure the ability of PMFMDA to predict miRNAs associated with novel diseases. We conduct CV testing on 8 common diseases, which have at least 80 associations are verified ([@B33]). PMFMDA achieves the highest average AUPRs of 0.6687. Finally, to make the more comprehensive test of PMFMDA, we use the three most common diseases in humans for research. The number of other database validations in the top 20 predicted miRNAs for esophageal tumors, breast tumors, and lung tumors are found to be 20, 19, and 17, respectively. In conclusion, PMFMDA has achieved good results in predicting the potential association of miRNA disease and predicting new disease-associated miRNAs and can be used as a very useful supplement to existing prediction models.

Although quite satisfactory results have been achieved from PMFMDA, there are still some limitations to this approach. Firstly, we only use semantic similarity and the Gaussian kernel similarity to construct disease similarity network. It may be helpful to improve the predictive performance of PMFMDA by integrating disease or miRNA similarity from multiple data sources such sequence similarity. Secondly, the public data sets used in this study may have noise and outliers. A preprocessing step for de-noising and dimension reduction in raw input data might be useful. Thirdly, in the process of solving PMFMDA, the gradient descent method often obtains the local optimal solution, and how to further optimize its solution helps to improve the prediction performance of PMFMDA. Finally, as more and more miRNAs and disease associations are confirmed, collecting more validated data will help us to conduct more in-depth research.
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